Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy, to strengthen its clinical-stage pipeline, according to a press release.
“Glaucoma treatment has always been focused on lowering IOP, but patients are still losing field of vision and quality of vision, especially in dim light conditions,” Yehia Hashad, MD, chief medical officer and executive vice president of research and development at Bausch + Lomb, told Healio. “Bausch + Lomb is investing in the first treatment that could potentially address both